Effects of adiposity on the human plasma proteome: Observational and Mendelian randomization estimates

Short title: Adiposity and proteins

Authors

Lucy J. Goudswaard[1, 2, 3], Joshua A. Bell[1, 2], David A. Hughes[1, 2], Laura J. Corbin[1, 2], Klaudia Walter[4], George Davey Smith[1, 2], Nicole Soranzo[4, 5, 7], John Danesh[4, 6, 7, 8, 9, 10], Emanuele Di Angelantonio[6, 7, 8, 9, 10], Willem H. Ouwehand[4, 5, 8, 11], Nicholas A. Watkins[11], David J. Roberts[7, 12, 13], Adam S. Butterworth[6, 7, 8, 9, 10], Ingeborg Hers[3, 14], Nicholas J. Timpson[1, 2]

Affiliations

[1] Medical Research Council (MRC) Integrative Epidemiology Unit at the University of Bristol, Bristol, UK

[2] Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

[3] School of Physiology, Pharmacology and Neuroscience, University of Bristol, UK

[4] Wellcome Sanger Institute, Hinxton, UK

[5] Department of Haematology, School of Clinical Medicine, University of Cambridge, UK

[6] MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.

[7] NIHR Blood and Transplant Research Unit in Donor Health and Genomics, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK

[8] British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK.

[9] NIHR Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals, Cambridge, UK

[10] Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK

[11] NHS Blood and Transplant, Cambridge Biomedical Campus, Long Road, Cambridge, UK

[12] NHS Blood and Transplant-Oxford Centre, Level 2, John Radcliffe Hospital, Oxford, UK

[13] Radcliffe Department of Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK

[14] Bristol Heart Institute, Bristol, UK

Abstract words: 385, **Total words**: 7859; **References:** 52, **Tables:** 3, **Figures:** 4, **Appendices:** 2

Acknowledgments:

Participants in the INTERVAL randomised controlled trial were recruited with the active collaboration of NHS Blood and Transplant England (www.nhsbt.nhs.uk), which has supported field work and other elements of the trial. DNA extraction and genotyping was co-funded by the National Institute for Health Research (NIHR), the NIHR BioResource (http://bioresource.nihr.ac.uk) and the NIHR [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]*. The academic coordinating centre for INTERVAL was supported by core funding from: NIHR Blood and Transplant Research Unit in Donor Health and Genomics (NIHR BTRU-2014-10024), UK Medical Research Council (MR/L003120/1), British Heart Foundation (SP/09/002; RG/13/13/30194; RG/18/13/33946) and the NIHR [Cambridge Biomedical Research Centre at the Cambridge University Hospitals NHS Foundation Trust]. A complete list of the investigators and contributors to the INTERVAL trial is provided in this reference (1). The academic coordinating centre would like to thank blood donor centre staff and blood donors for participating in the INTERVAL trial.

This work was supported by Health Data Research UK, which is funded by the UK Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care (England), Chief Scientist Office of the Scottish Government Health and Social Care Directorates, Health and Social Care Research and Development Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart Foundation and Wellcome. This work was also supported by the Wellcome Trust grant number 206194.

*The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Funding: This publication is the work of the authors who are guarantors for its contents. LJG is funded by the University of Bristol alumni on the 4-year BHF Integrative Cardiovascular Science PhD programme. JAB is supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol and the Wellcome Trust Institutional Strategic Support Fund (204813/Z/16/Z). DAH and LJC are funded by the Wellcome Trust (202802/Z/16/Z). KW is supported by the Wellcome Trust. GDS works in the Medical Research Council Integrative Epidemiology Unit at the University of Bristol, which is supported by the Medical Research Council (MC_UU_00011/1). NS is supported by the Wellcome Trust, British Heart Foundation and NIHR funding to the Cambridge Bioresource. JD is funded by the National Institute for Health Research (Senior Investigator Award). IH is supported by the EPSRC Prostanoid programme (EP/M012530/1) and BHF (PG/16/3/31833). NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 102215/2/13/2), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-20011), the MRC Integrative Epidemiology Unit (MC_UU_12013/3) and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: GDS is a PLOS Medicine editorial board member. John Danesh sits on the International Cardiovascular and Metabolic Advisory Board for Novartis (since 2010); the Steering Committee of UK Biobank (since 2011); the MRC International Advisory Group (ING) member, London (since 2013); the MRC High Throughput Science 'Omics Panel Member, London (since 2013); the Scientific Advisory Committee for Sanofi (since 2013); the International Cardiovascular and Metabolism Research and Development Portfolio Committee for Novartis; and the Astra Zeneca Genomics Advisory Board (2018).

Abstract

Background: Variation in adiposity is associated with cardiometabolic disease outcomes, but the mechanisms leading from this exposure to disease are unclear. This study aimed to estimate effects of adiposity, proxied by body mass index (BMI), on an extensive set of circulating proteins using both observational and genetically informed analyses.

Methods and findings: We used proteomic data from up to 2,737 healthy participants from the INTERVAL study of UK blood donors. Associations between self-reported BMI and 3,622 unique plasma proteins measured by the SomaLogic platform were explored using linear regression. These were complemented by Mendelian randomization (MR) analyses using a genetic risk score (GRS) comprised of 654 BMI-associated polymorphisms from a recent genome-wide association study (GWAS) of adult BMI. Observationally, BMI showed associations with 1,576 protein traits (Bonferroni corrected $P < 1.4 \times 10^{-5}$), with strong associations with leptin, fatty acid-binding protein 4 (FABP4) and sex hormone binding globulin (SHBG). The GRS for BMI was positively associated with self-reported BMI to the extent expected given its known genetic association ($R^2 = 0.028$) and there was a lack of strong association between this GRS and measured confounding factors. MR analyses provided further evidence for a causal relationship between BMI and a range of measured proteins (eight in this analysis achieved $P < 1.4 \times 10^{-5}$) including a strong relationship with leptin levels (0.63 standard deviation (SD) per SD BMI, 95% CI 0.48 to 0.79, $P = 1.6 \times 10^{-15}$), FABP4 (0.64 SD per SD BMI, 95% CI 0.46 to 0.83, $P = 6.7 \times 10^{-12}$) and SHBG abundance (-0.45 SD per SD BMI, 95% CI -0.65 to -0.25, $P = 1.4 \times 10^{-5}$). There was strong agreement in the direction and magnitude of observational and MR estimates ($R^2 = 0.33$) and evidence that proteins most strongly altered by BMI were enriched for genes involved in cardiovascular disease (1.14 fold enrichment, $P = 1.3 \times 10^{-4}$). Limitations of this particular set of analyses include a modest sample size and a derivation of measured BMI from self-reported height and weight.

Conclusions: This study provides evidence for a broad impact of adiposity on the human proteome. Proteins most strongly altered by BMI include those which are involved in regulating appetite, sex hormones, and inflammation; such proteins are also enriched for genes related to cardiovascular disease. These results help to focus attention onto new potential targets for obesity-related disease prevention.

Introduction

Obesity has tripled worldwide since 1975, now affecting around 40% of adults in the United States

and 26% of adults in the UK (2). The average body mass index (BMI) of the UK adult population is

now in the conventional 'overweight' category (BMI between 25 and 30 kg/m^2) (3), and 'overweight' is

now more common than 'normal-weight' in middle age in many high-income countries (4). BMI is

often used as a proxy for adiposity given high correlations between BMI and more objectively

measured fat mass indices (5). Higher adiposity is a major risk factor for various noncommunicable

diseases including type II diabetes, cardiovascular diseases, musculoskeletal diseases, and cancer

(6-9), which collectively put a substantial strain on health services (10, 11). These BMI-disease

associations are supported by prospective observational studies and, more recently, by Mendelian

randomization (MR) studies (12-14), which use the naturally random assignment of adiposity-

associated risk alleles to estimate effects of BMI on disease outcomes. This method helps to

overcome issues such as confounding and reverse causation which commonly occur with

observational studies (15).

Despite MR studies supporting a causal role of adiposity for cardiometabolic diseases, and

randomised trials supporting the effectiveness of weight loss in reducing disease risk (17), the

molecular footprint of adiposity is not well understood. Previous studies have largely focused on the

impact of higher BMI on the lipidome including traits such as cholesterol and triglycerides in

lipoprotein subtypes (e.g. low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and high-

density lipoprotein (HDL) particles) (5, 18), and on inflammatory molecules such as C-reactive protein

(CRP) (18, 19). Efforts to study the effect of BMI on the broader proteome have generally been in an

observational framework (20), with no studies using MR to investigate the impact of BMI on a

comprehensive set of protein traits measured in circulation. This has only recently become possible

with newly developed proteomic technologies such as the SomaLogic platform. It is estimated that

around 25% of proteins in the human proteome circulate in blood (21), which allows SomaLogic to

quantify circulating traits including enzymes, protein kinases and transport proteins in unprecedented

scope and detail (22). This research is important because the majority of druggable targets are such

proteins (23). Identifying proteins which are altered by BMI may allow for the development or

repurposing of therapeutic interventions to reduce the impact of BMI on disease.

In this study, we aimed to measure associations between adiposity and the human proteome and to

also estimate the underlying effects in a causal framework. Using data on 2,737 participants from a

cohort study of blood donors in England (INTERVAL), we estimated effects of BMI on 4,034 (3,622

unique) plasma protein traits, in both observational and MR frameworks. We examined the agreement

between effect estimates from different methods and then performed enrichment analyses of the most

strongly altered proteins to map their potential relevance to cardiovascular diseas

Methods

Study population

INTERVAL is a prospective cohort study which was initially a randomised trial that aimed to test the

efficiency and safety of reducing the time between whole blood donation in approximately 50,000

participants (1). Upon informed consent, eligible participants who were: aged 18 years and over,

willing to complete online questionnaires and without a self-reported history of major disease were

recruited between June 11th, 2012 and June 15th, 2014 from 25 National Health Service Blood and

Transplant (NHSBT) centres across England. Participants filled out questionnaires including self-

reported height and weight, smoking frequency and alcohol consumption. Blood samples were taken

at baseline which were analysed for full blood counts and blood biomarkers. This study was approved

by Cambridge (East) Research Ethics Committee. Access to the data was granted by the Data

Access Committee. Data cannot be publicly shared due to sensitive content. General enquiries can

be sent to the INTERVAL team https://www.intervalstudy.org.uk/more-information/.

The present study was conducted on a random subset of participants from INTERVAL who had

plasma proteins measured by SomaLogic. This included up to 2,737 participants mostly of European

descent across analyses described below.

Assessment of BMI and covariables

Participants completed online questionnaires wherein they reported their height and weight. BMI was

calculated as weight in kilograms divided by the square of their height in metres (kg/m^2). Available

covariables were age, sex, previous or current smoking frequency (in three categories of: never,

occasional, most days or every day) and alcohol intake frequency (in four categories of: rarely, less

than once a week, 1-2 times a week, 3-5 times a week or most days). These covariables were chosen

as they were measured in the INTERVAL collection and are measures which have known

relationships with adiposity and cardiometabolic health.

Measurement of circulating proteins

Plasma proteins were measured in INTERVAL participants at baseline (before randomisation of

assignment to the time interval between blood donation) using the SomaScan® by SomaLogic. This

platform uses 4,034 modified nucleotides known as Slow Off-rate Modified Aptamers (SOMAmers)

which make direct contact with proteins, enabling detection of 3,622 unique proteins or protein

complexes and quantifies them using a DNA microarray (22). These proteins include growth factors,

cytokines, protein kinases, and transport proteins. The proteins were measured in relative

fluorescence units (RFUs) and quality control (QC) was performed as described by Sun et al. (24).

There was no missingness across protein variables. The proteomic data used had been pre-adjusted

for: age, sex, duration between blood draw and sample processing (1 day or less vs >1 day), and the

first three genetic principal components, with the residuals inverse normal rank transformed.

Genetic data and instrument for BMI

108 INTERVAL participant genotyping was performed on the Affymetrix GeneTitan® Multi-Channel (MC)

109 Instrument and the QC of genotype data was implemented as described by Astle et al. (25). The

110 imputation panel used was the 1000 genomes phase-3-UK-10K (25). A genetic instrument for BMI

111 was constructed using 654 genetic variants that were associated with BMI at $P < 1 \times 10^{-8}$ in the

112 inverse variance weighted fixed-effect meta-analysis of GWAS of ~700,000 individuals of European

ancestry (26). This meta-analysis consisted of ~250,000 adults from the Genetic Investigation of

ANthromopetric Traits (GIANT) consortium (27) and ~450,000 adults from the UK Biobank study. Only

0.05% of UK Biobank participants were included in the INTERVAL study. These participants were not

excluded to increase power. The weighted GRS was made using PLINK 2.0 software (28) using the

effect alleles and beta coefficients from the source GWAS. The score was calculated by multiplying

the number of effect alleles at each SNP by its weighting or effect estimate (beta), summing these,

and dividing by the total number of SNPs included. The GRS therefore can be interpreted as the

average per-SNP effect on BMI for each individual.

Statistical analyses

The population characteristics of INTERVAL participants with SomaLogic data who were included in

this study (N range: 2,422 to 2,737) were compared to those INTERVAL participants who were not

included (N range: 27,174 to 30,721). Population characteristics evaluated were age, sex, weight,

height, BMI, smoking frequency, and alcohol intake. Differences among the two INTERVAL sub-sets

were tested by a two-sided t-test for continuous traits and a two-sided Chi-square test for categorical

variables. Observational analyses were conducted using linear regression models to examine

associations between BMI (in normalized standard deviation (SD) units based on a rank normal

transformation) and each standardised protein trait as a dependent (outcome) variable. Two models

were used: 1) adjusted for age and sex and 2) additionally adjusted for smoking and alcohol

consumption (each as an ordered categorical variable). These estimates therefore reflect the

normalized SD-unit difference in each protein trait per normalized SD-unit (4.8 kg/m^2) higher BMI.

Associations of covariables with BMI and protein traits were also examined using linear regression to

affirm their potential roles as confounders of associations between BMI and protein traits.

A Shapiro-Wilk test was used to test whether the GRS showed a normal distribution. MR analyses

were conducted using two-stage least squares (2SLS) regression models with robust standard errors,

with measured BMI in SD units and the GRS for BMI as the instrumental variable. These MR

estimates reflect the normalized SD-unit difference in each protein trait per normalized SD-unit (4.8

kg/m^2) higher BMI. Agreement between observational and MR estimates was examined using a

separate linear regression model (based on the beta coefficients from observational and MR

analyses), with a regression slope nearer one and a higher R^2 reflecting stronger agreement between

estimates. This was performed: 1) for all proteins, and 2) excluding the proteins that fell below our P-

value reference point for strong evidence (defined below) to examine whether agreement is limited to

'top hits' or applies throughout the effect distribution.

Given that multiple statistical tests were performed, a Bonferroni correction was used to penalise

results. This was informed by the correlation between proteins, adjusting only for the estimated

number of independent traits (**Supplementary Fig 1**). Correlation was assessed by a Spearman's

correlation matrix. From a starting number of 4,034, the number of independent proteins was 3,655

(using a correlation cut-off of r = 0.8 / tree cut height = 0.2 between proteins, **Supplementary Fig 2**).

As a heuristic for grading the strength of evidence given current sample sizes, we utilise a Bonferroni

adjusted P-value of $< 1.4 \times 10^5$ (which corresponds to an approximate 0.05 level (0.05/3655)) to

indicate strong evidence in this sample. Results are presented in full in the supplementary material

with exact P-values, effect sizes, and 95% confidence intervals.

To investigate whether any proteins showed a particularly strong relationship with BMI and disease

(signal detection), protein features were clustered for further analysis. Firstly, a principal component

analysis (PCA) was performed on the inverse normal rank transformed protein dataset to generate

components explaining correlated features and to reduce the dataset. The number of principal

components (PCs) was chosen to convey most of the dataset while reducing the number of variables;

this was selected by visualising the 'elbow' of a scree plot (**Supplementary Fig 3)**. Derived PCs were

then entered into a k-means analysis to create clusters of similar proteins. The number of clusters

was chosen as the 'elbow' of a scree plot of the number of protein groups against how much variance

of the dataset is explained by clusters.

To explore whether there was a systematic difference in the association of proteins within these

clusters and BMI among clusters, the beta coefficients from the observational linear regressions or

MR models were transformed into their absolute values and divided by their standard error (SE). The

mean of the absolute beta divided by SE in each cluster was compared using a one-tailed pairwise

Wilcox test to identify which clusters showed a stronger association with BMI. For the cluster(s)

showing evidence for larger absolute beta coefficients, an enrichment analysis was performed using

DAVID bioinformatics resources 6.8 (29). Enrichment was assessed by using the uniprot IDs for the

proteins in the cluster and comparing these proteins with the uniprot IDs of the full SomaLogic protein

list. Enrichment for protein involvement in disease (using the genetic association database (GAD)

disease classes (30)) of the protein cluster was assessed by fold enrichment and a Bonferroni-

corrected P value to account for multiple testing. As well as looking at cluster enrichment, the proteins

that were associated with BMI in confounder-adjusted observational analyses at $P < 1.4 \times 10^{-5}$ were

entered into the disease enrichment tool and compared with the total proteins (as described for

cluster enrichment).

Analyses were performed using R version 3.4.2 (31).

Results

Participant characteristics

INTERVAL participants included in this study (those with proteomic data), had a mean age of 45.0

years (SD of 14.1 years) and 48.3% were female (**Table 1**). Mean BMI was 25.9 kg/m^2 (SD of 4.8

kg/m^2) and the majority of participants were non-smokers (59.1%). Nearly a quarter (23.5%) reported

currently or previously smoking daily and 71.5% reported drinking alcohol at least once a week.

Table 1. Characteristics of included participants

Variable		Mean (SD) or %	N
Age (years)		45.0 (14.1)	2,737
Sex	**Male**	51.7 %	2,737
	Female	48.3 %	
Weight (kg)		78.5 (16.1)	2,736
Height (cm)		172.7 (9.7)	2,730
Body mass index (kg/m^2)		25.9 (4.8)	2,729
Smoking frequency	**Never**	59.1 %	2,675
	Occasional	11.9 %	

	Most days or every day	29.0 %	
Alcohol intake frequency	Rarely	11.7 %	2,422
	Less than once a week	16.9 %	
	One or two times a week	37.4 %	
	Three to five times a week / most days	34.1 %	

Compared with participants who were included in analyses, those who were excluded were of similar

age, had a similar BMI and similar drinking and smoking habits (**Supplementary Table 1**). There was

a slightly smaller proportion of females included in the analysis compared with excluded participants

(48.3% and 50.3% respectively, P = 0.04).

Observational estimates of associations of BMI with protein traits

In a linear regression model adjusted for age and sex among 2,729 adults, BMI (per SD higher) was

associated with 1,576 proteins at the level $P < 1.4 \times 10^{-5}$ (multiple testing reference point)

Supplementary Table 2). In a second model additionally adjusting for frequencies of smoking and

alcohol intake among 2,380 adults, there were 1,447 associations at the same reference point

(**Supplementary Table 3**). The strongest positive associations were with leptin (0.74 SD, 95% CI

0.71 to 0.77, $P = 9.9 \times 10^{-324}$) and adipocyte fatty acid binding protein (FABP4) (0.58 SD, 95% CI 0.55

to 0.62, $P = 6.4 \times 10^{-211}$). BMI (per SD) was also strongly positively associated with inflammatory

proteins such as Complement Factor I (0.46 SD, 95% CI 0.43 to 0.50, $P = 5.6 \times 10^{-122}$) and CRP (0.44

SD, 95% CI 0.41 to 0.48, $P = 8.2 \times 10^{-112}$). BMI (per SD) also showed strong negative associations

with proteins such as insulin-like growth factor-binding protein (IGFBP) 2 (-0.48 SD, 95% CI -0.51 to -

0.44, $P = 2.7 \times 10^{-133}$) and sex hormone-binding globulin (SHBG) (-0.43 SD, 95% CI -0.47 to -0.39, P

$= 2.4 \times 10^{-106}$).

Observational associations of covariables with BMI and protein traits

Age, sex, and frequencies of smoking and alcohol intake were each associated with BMI

(**Supplementary Table 4**). Males had a higher BMI than females (0.17 SD, 95% CI 0.10 to 0.25, P =

5.8 x 10^{-6}). Age was positively associated with BMI (0.01 SD higher per year older, 95% CI 0.009 to

0.015, P = 1.2 x 10^{-18}). Smoking frequency was also positively associated with BMI (0.09 SD higher

BMI per increase in smoking category, 95% CI 0.05 to 0.13, P = 3.2 x 10^{-5}). Alcohol intake frequency

was negatively associated with BMI (-0.08 SD decrease in BMI per increase in alcohol intake

category, 95% CI -0.12 to -0.04, P = 7.1 x 10^{-5}). The exposures age, sex, and frequencies of smoking

and alcohol intake each also showed associations with protein traits (**Supplementary Tables 5-8** and

Supplementary Figs 4A-D).

Associations of the GRS for BMI with measured BMI and covariables

The distribution of the GRS among participants was normal (mean = 0.08, SD = 0.29, W = 0.99, P =

0.73, **Fig 1A**). The GRS was strongly associated with BMI in INTERVAL based on self-reported

height and weight, explaining 2.8% of its variance (R^2 = 0.028, P = 1.6 x 10^{-18}, **Fig 1B** and **Table 2**).

There was no strong evidence of association between GRS and age (R^2 = 0.001, P = 0.11), sex (R^2 =

6 x 10^{-5}, P = 0.28), smoking frequency (R^2 = < 0.0001, P = 0.91), or alcohol intake (R^2 < 0.0001, P =

0.44).

Fig 1 – The genetic risk score shows a normal distribution and associates with reported BMI

A) Distribution of the genetic risk score for BMI in INTERVAL, **B**) Scatter plot of the genetic risk score

for BMI against reported BMI in INTERVAL with the linear regression line (blue, N=2729).

Table 2 – Associations of the genetic risk score for BMI with reported BMI and covariables

Variable	N	Beta coefficient (per 1-unit increase in GRS)	Standard error	P value	Adjusted R^2	F statistic
BMI (SDs)	2729	0.57	0.06	1.64×10^{-18}	0.028	78.20
BMI (kg/m²)	2729	2.54	0.31	4.82×10^{-16}	0.024	66.68
Age (years)	2737	-1.47	0.92	0.11	0.001	2.55
Sex (1 = female, 2 = male)	2737	-0.04	0.03	0.28	5.96E-05	1.16
Smoking frequency (1 = never, 2 = occasional, 3 = most days or every day)	2675	-0.02	0.14	0.91	-0.0004	0.01
Alcohol intake frequency (1 = rarely, 2 = < 1 a week, 3 = 1-2 times a week, 4 = most days or every day)	2422	-0.06	0.07	0.44	-0.0002	0.60

MR estimates of associations between BMI and protein traits

238 In MR analyses, eight unique BMI-protein associations were detected at the level $P < 1.4 \times 10^{-5}$

240 (multiple testing reference point, **Fig 2**). The strongest association of BMI (per SD) was again with

241 leptin (0.63 SD, 95% CI = 0.48 to 0.79; $P = 1.6 \times 10^{-15}$); this was followed by the association with

242 FABP4 (0.65 SD, 95% CI = 0.46 to 0.83; $P = 6.7 \times 10^{-12}$). A strong negative association was also seen

243 between BMI (per SD) and SHBG (-0.45 SD, 95% CI -0.65 to -0.25, $P = 1.4 \times 10^{-5}$). Other BMI-protein

244 associations (below a P-value reference point of 1.4×10^{-5}) included positive associations with

245 fumarylacetoacetase, inhibin β C chain and complement C5, and negative associations with receptor-

246 type tyrosine-protein phosphatase delta and PILR alpha-associated neural protein. **Supplementary**

247 **Table 9** provides the full MR results for BMI and protein traits**.**

Fig 2 – Strongest BMI and MR associations with corresponding observational associations

Strongest MR results of BMI and protein traits based on P value < 1.4 x 10^{-5} and their corresponding

observational estimates.

Comparison of observational and MR estimates

The distribution of P-values for associations between BMI and protein traits suggested an

overrepresentation of signal for the observational estimates of BMI and protein traits; far more than

expected from chance alone (**Supplementary Fig 5A**). In contrast to this, whilst there was still more

signal than expected by chance for a large number of traits in MR analyses, the extent of this

overrepresentation was reduced considerably (**Supplementary Fig 5B**).

The unadjusted and confounder-adjusted regression coefficients for BMI and protein traits were very

strongly associated (β = 0.99 SDs, R^2 = 0.99, P = 9.9 x 10^{-324} **Fig 3A**). Compared with the

observational estimates, the MR estimates were less precise, but there was a strong positive

association between the beta coefficients from observational and MR estimates (β = 0.68 SDs, R^2 =

0.33, P = 9.9 x 10^{-324}) (**Fig 3B)**. After removing the proteins that were below the Bonferroni-corrected

reference P-value of 1.4 x 10^{-5}, the strength of association between unadjusted and adjusted

observational estimates remained, but the association between observational and MR estimates

attenuated slightly (**Supplementary Figs 6A/B**).

275 **Fig 3 – Observational and MR estimates show a positive association**

A) Scatter plot of the unadjusted (age and sex adjusted) observational estimates and the confounder-

adjusted observational estimates for BMI and protein traits with a regression line (blue). **3B**) Scatter

plot of the unadjusted (age and sex adjusted) observational estimates and the MR estimates for BMI

and protein traits with a regression line (blue).

Enrichment analysis of strongest BMI-protein associations

In examining the clustering of proteins, visual representation using a scree plot suggested there were

five PCs (**Supplementary Fig 3**). These five PCs were entered into a k-means analysis, which

provided evidence for five clusters (grouping of individual proteins is included in **Supplementary**

Table 9). To identify which cluster was most strongly affected by BMI, the mean absolute beta

coefficient divided by the SE for each cluster was compared with the overall estimate. The beta

coefficients for each BMI-protein effect, grouped by cluster can be seen in **Figs 4A** and **4B**). Six of the

proteins out of the eight strongest BMI-protein MR estimates were in cluster 2 (**Supplementary Fig**

9). There was consistent evidence that cluster 2 showed a stronger association with BMI than the

overall average BMI-protein effect both observationally (5.2 (SD 5) vs 4.38 (SD 4.16) respectively, P =

3.7×10^{-4}) and in MR (1.04 (SD 0.84) vs 0.9 (SD 0.74), P = 5.3×10^{-6}, **Supplementary Table 10, Figs**

4C and 4D). Cluster 2 showed consistent evidence of a having the largest BMI effect. Compared with

the full protein list in SomaLogic, the proteins in cluster 2 were enriched for disease (**Table 3**),

including cardiovascular disease (1.14 fold enrichment, P = 1.3×10^{-4}), renal disease (1.22 fold

enrichment, P = 1.0×10^{-3}) cancer (1.1 fold enrichment, P = 9.5×10^{-3}) and metabolic disease (1.08

fold enrichment, P = 4.2×10^{-2}). No other individual cluster showed enrichment for disease.

Enrichment for disease was also explored by comparing the proteins which had an association with

BMI (P < 1.4×10^{-5}) in the confounder-adjusted regression model with the total protein list. Compared

with the full protein list, the proteins which showed a stronger observational association with BMI were

enriched for renal disease (1.21 fold enrichment, P = 0.001) and metabolic disease (1.9 fold

enrichment, P = 0.015, **Supplementary Table 11**).

     Fig 4 – Cluster 2 shows larger absolute observational and MR BMI-protein estimates

327 A

B

C

D

A) Volcano plot showing the beta coefficients and -$\log_{10}$(P value) for each unadjusted observational

BMI-protein association, with colour indicating the grouping by cluster. **B)** Volcano plot showing the

beta coefficients and -$\log_{10}$(P value) for each BMI-protein Mendelian randomization (MR) estimate

with colour indicating the grouping by clustering. **C)** Violin plot of the absolute beta coefficients divided

by standard error for each BMI-protein association for the unadjusted observational model, grouped

by cluster (mean ± SD plotted). **D)** Violin plot of the absolute beta coefficients for each BMI-protein

Mendelian randomization estimate divided by the standard error, grouped by cluster (mean ± SD).

Table 3. Cluster 2 vs full SomaLogic protein enrichment results for disease class using DAVID

bioinformatics 6.8 (29)

Term (Genetic Association Database disease class)	Count	%	List Total	Population Hits	Population Total	Fold Enrichment	P Value	Bonferroni
Cardiovascular	439	34.1	1024	1023	2723	1.14	7.3E-06	1.3E-04
Renal	216	16.8	1024	472	2723	1.22	5.8E-05	1.0E-03
Cancer	401	31.2	1024	958	2723	1.11	5.3E-04	9.5E-03
Pharmacogenomic	357	27.8	1024	856	2723	1.11	1.9E-03	3.4E-02
Metabolic	504	39.2	1024	1243	2723	1.08	2.4E-03	4.2E-02
Vision	100	7.8	1024	216	2723	1.23	5.9E-03	1.0E-01
Haematological	168	13.1	1024	388	2723	1.15	9.8E-03	1.6E-01
Reproduction	152	11.8	1024	351	2723	1.15	1.4E-02	2.3E-01
Immune	360	28.0	1024	886	2723	1.08	1.5E-02	2.4E-01
Neurological	311	24.2	1024	759	2723	1.09	1.6E-02	2.5E-01
Aging	117	9.1	1024	278	2723	1.12	7.5E-02	7.5E-01

Discussion

We aimed in this study to estimate the effects of adiposity on the human proteome using

observational and MR methods and a comprehensive set of protein traits only recently measurable by

untargeted proteomics. Our results suggest that increased adiposity alters numerous protein traits

involved in regulating appetite, sex hormones, inflammation, and other systems; specific proteins

most altered by BMI include leptin, FABP4, and SHBG. Results of follow-up analyses suggest that the

cluster of proteins most altered by BMI is enriched for genes associated with cardiovascular disease.

Altogether, these results help to focus attention onto new potential targets for obesity-related disease

prevention.

This study to explored the effect of BMI on a comprehensive set of proteins in an MR framework. One

previous observational study explored the plasma proteome of people with obesity in two cohorts

using mass spectrometry (20), finding higher BMI to be associated with seven out of 182 or 299

proteins (3.8% and 2.3% respectively) compared with 1,576 (39%) BMI-protein associations in the

present study. An increase in Complement Factors I, B and H and an increase in CRP were observed

(20). These findings were replicated in our current observational analysis using the SomaLogic

platform, indicating that associations are detectable across different proteomic measurement

platforms. The only association that did not replicate in the current study was the positive association

with protein S100-A9. Although the MR analysis did not support some of these BMI-protein

associations as being causal based on a P-value reference point, the strong association between the

observational and MR estimates throughout the entire effect distribution suggests that disagreements

between methods are likely an issue of power given current sample sizes.

For the proteins with stronger MR derived association evidence, it is important to explore (where

possible) whether they have a potential role in disease. Our results suggest a strong positive effect of

BMI on levels of leptin – a hormone released by white adipose tissue which suppresses appetite (32).

The direction of effect we see currently agrees with estimates from previous cross-sectional and MR

studies (18, 33). As higher levels of leptin are expected to reduce appetite and thus adiposity, this

increase in circulating leptin seen with a higher BMI suggests that there is leptin receptor resistance

(34). This observation illustrates the complexity encountered when interpreting MR estimates of

causal effects and where, despite compelling association results, effect estimates can appear

counter-intuitive. In this case, the positive relationship between BMI and an appetite regulating protein

is a good illustration of the need to carefully explore the biology underpinning MR estimates before

deploying them in more applied contexts (such as interventions). Knockout studies in mice have

implicated higher leptin in arterial thrombosis (35) and there is observational evidence in humans that

higher leptin can induce greater aggregation of platelets (cells involved in haemostasis) (36). In a

larger population-based prospective observational study, leptin was found to be associated with

higher risk of coronary events independent of BMI (37), whilst another observational study found

leptin to be associated with higher risk of acute myocardial infarction (38).

Our results also suggest a strong positive effect of BMI on FABP4, an adipokine found primarily in

adipocytes and macrophages (39). This association has been suggested in previous observational

studies (40), but BMI-protein effect estimates from MR have been lacking. FABP4 has been

implicated in cardiometabolic disease: a SNP which increases FABP4 was found to raise the odds of

type II diabetes among adults (41), potentially through its contribution to higher insulin resistance (42).

FABP has also been associated with higher risk of atherosclerosis among adults in an observational

Chinese cohort study (43). A strong SHBG-lowering effect of higher BMI was also suggested here.

The SHBG molecule is a glycoprotein which binds androgens and oestrogens and suppresses their

activity (44); a reduction in SHBG is therefore expected to lead to higher levels of circulating sex

hormones. The negative effect of BMI on SHBG seen here supports findings of previous cross-

sectional studies among men (45) and post-menopausal women (46) and of a prospective study

among post-menopausal women (47). When evaluating the role of SHBG in disease, one MR

analysis suggests that a SNP which is associated with an increase in SHBG contributes to a decrease

in risk of cardioembolic stroke (48), thereby suggesting that the SHBG-lowering effect of higher BMI

observed in this study would increase this risk. Another study has also implicated lower SHBG levels

in increasing type II diabetes risk (41). SHBG has also been implicated in cardiometabolic disease in

observational studies. A study in over 3,000 men and women found that lower SHBG was associated

with poorer cardiovascular health as assessed by a scale composed of cholesterol, glucose, blood

pressure, BMI, diet, smoking, and physical activity (49). The exact mechanisms leading from

decreased SBHG to ill-health is unclear, but may arise as a result of the increased bioavailability of

testosterone and oestrogen (44).

Despite these possible protein involvements in cardiometabolic disease, it remains difficult to assess

the contribution of individual proteins as they are not entirely independent and any protein effects

would likely be due to a global change in protein composition. There are not distinct groupings in the

SomaLogic proteomics data as there often are with, for example, metabolomics data. We therefore

additionally examined proteins grouped into clusters of similar features and compared BMI-protein

estimates of each cluster with overall estimates and, for the cluster most affected by BMI, explored

enrichment for genes related to disease. The cluster most altered by BMI (cluster 2) included most of

the eight proteins with the strongest BMI effects from MR analyses, as well as various complement

factors, chemokines, coagulation factors and IGFBPs, and was found to be enriched for genes related

to cardiovascular disease, renal and metabolic diseases, and cancer. Enrichment was similar when

comparing the proteins that had an observational association with BMI with all proteins included, with

enrichment appearing greatest for renal and metabolic disease. Together, this suggests that changes

in proteins identified here may mediate effects of obesity on cardiometabolic diseases; more focused

investigations of these proteins are now needed.

Limitations

This study has some limitations. Firstly, although INTERVAL is one of the largest existing cohorts to

have untargeted proteomic data based on the SomaLogic platform, the sample size is still relatively

modest and may have low power to detect some associations when using MR. Despite this, there was

high agreement in the magnitude of effect estimates seen in observational and MR analyses which

applied throughout the effect distribution. Participants with proteomic data were a small subset of the

full INTERVAL cohort, however, this subset was randomly selected for proteomic assessment and

comparisons between included and excluded participants revealed a similar profile in terms of age,

sex, BMI, smoking, and alcohol use. Height and weight were self-reported which could introduce

measurement error and bias; however, strong correlations are often reported between self-reported

and measured BMI (50) and the validity of self-reported BMI here is supported by the strong positive

association between the GRS for BMI (which was based largely on clinic-measured height and

weight) and self-reported BMI in INTERVAL. Another limitation is the lack of availability of possible

confounders for observational analyses. Although participants reported smoking and drinking habits,

other potential confounders such as indicators of socio-economic position (which likely affect both

BMI and protein traits related to cardiovascular disease processes (51, 52)) were not available.

Residual confounding may help account for the much larger divergence between observed and

expected P-values seen in observational versus MR models. The proteins examined are highly

correlated and we therefore may not fully be describing changes in individual proteins. Evidence from

case-control cohorts as well as functional and animal studies would help to isolate individual proteins

that are altered and contribute to disease.

Conclusions

The results of this study support a broad impact of higher adiposity on the human proteome. Causal

evidence was strongest for BMI in relation to proteins involved in regulating appetite, sex hormones,

and inflammation; such proteins were also found to be enriched for genes related to cardiovascular

disease. Altogether, these results help to focus attention onto new potential targets for obesity-related

disease prevention.

References

1.   Di Angelantonio E, Thompson SG, Kaptoge S, Moore C, Walker M, Armitage J, et al.

Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised

trial of 45 000 donors. Lancet. 2017;390(10110):2360-71.

2.   Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol.

2019;15(5):288-98.

3.   Wade KH, Carslake D, Sattar N, Davey Smith G, Timpson NJ. BMI and Mortality in UK

Biobank: Revised Estimates Using Mendelian Randomization. Obesity (Silver Spring).

2018;26(11):1796-806.

4.   (NCD-RisC) NRFC. Trends in adult body-mass index in 200 countries from 1975 to 2014: a

pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet.

2016;387(10026):1377-96.

5.   Bell JA, Carslake D, O'Keeffe LM, Frysz M, Howe LD, Hamer M, et al. Associations of Body

Mass and Fat Indexes With Cardiometabolic Traits. J Am Coll Cardiol. 2018;72(24):3142-54.

6.   Garg SK, Maurer H, Reed K, Selagamsetty R. Diabetes and cancer: two diseases with

obesity as a common risk factor. Diabetes Obes Metab. 2014;16(2):97-110.

7.   Khan SS, Ning H, Wilkins JT, Allen N, Carnethon M, Berry JD, et al. Association of Body

Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity. JAMA

Cardiol. 2018;3(4):280-7.

8.   Kortt M, Baldry J. The association between musculoskeletal disorders and obesity. Aust

Health Rev. 2002;25(6):207-14.

9.   Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L. Body-mass index

and risk of 22 specific cancers: a population-based cohort study of 5·24 million UK adults. Lancet.

2014;384(9945):755-65.

10.   Dixon P, Davey Smith G, Hollingworth W. The Association Between Adiposity and Inpatient

Hospital Costs in the UK Biobank Cohort. Appl Health Econ Health Policy. 2019;17(3):359-70.

11.   Dixon P, Hollingworth W, Harrison S, Davies NM, Smith GD. The causal effect of adiposity on

hospital costs: Mendelian Randomization analysis of over 300,000 individuals from the UK Biobank.

bioRxiv. 2019:589820.

12.   Nordestgaard BG, Palmer TM, Benn M, Zacho J, Tybjaerg-Hansen A, Davey Smith G, et al.

The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a

Mendelian randomisation approach. PLoS Med. 2012;9(5):e1001212.

13.   Dale CE, Fatemifar G, Palmer TM, White J, Prieto-Merino D, Zabaneh D, et al. Causal

Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes,

and Type 2 Diabetes Mellitus: A Mendelian Randomization Analysis. Circulation. 2017;135(24):2373-

88.

14.   Carreras-Torres R, Johansson M, Gaborieau V, Haycock PC, Wade KH, Relton CL, et al. The

Role of Obesity, Type 2 Diabetes, and Metabolic Factors in Pancreatic Cancer: A Mendelian

Randomization Study. J Natl Cancer Inst. 2017;109(9).

15.   Smith GD, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to

understanding environmental determinants of disease? Int J Epidemiol. 2003;32(1):1-22.

16.   Mariosa D, Carreras-Torres R, Martin RM, Johansson M, Brennan P. Commentary: What can

Mendelian randomization tell us about causes of cancer? International Journal of Epidemiology.

2019;48(3):816-21.

17.   Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of

modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with

type 2 diabetes. Diabetes Care. 2011;34(7):1481-6.

18.   Würtz P, Wang Q, Kangas AJ, Richmond RC, Skarp J, Tiainen M, et al. Metabolic signatures

of adiposity in young adults: Mendelian randomization analysis and effects of weight change. PLoS

Med. 2014;11(12):e1001765.

19.   Timpson NJ, Nordestgaard BG, Harbord RM, Zacho J, Frayling TM, Tybjærg-Hansen A, et al.

C-reactive protein levels and body mass index: elucidating direction of causation through reciprocal

Mendelian randomization. Int J Obes (Lond). 2011;35(2):300-8.

20.   Cominetti O, Núñez Galindo A, Corthésy J, Valsesia A, Irincheeva I, Kussmann M, et al.

Obesity shows preserved plasma proteome in large independent clinical cohorts. Sci Rep.

2018;8(1):16981.

21.   Gold L, Walker JJ, Wilcox SK, Williams S. Advances in human proteomics at high scale with

the SOMAscan proteomics platform. N Biotechnol. 2012;29(5):543-9.

22.   Rohloff JC, Gelinas AD, Jarvis TC, Ochsner UA, Schneider DJ, Gold L, et al. Nucleic Acid

Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and

Therapeutic Agents. Mol Ther Nucleic Acids. 2014;3:e201.

23.   Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug

targets. Nat Rev Drug Discov. 2006;5(10):821-34.

24.   Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas of

the human plasma proteome. Nature. 2018;558(7708):73-9.

25.   Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The Allelic Landscape of

Human Blood Cell Trait Variation and Links to Common Complex Disease. Cell. 2016;167(5):1415-

29.e19.

26.   Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, et al. Meta-analysis of

genome-wide association studies for height and body mass index in ~700000 individuals of European

ancestry. Hum Mol Genet. 2018;27(20):3641-9.

27.   Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body

mass index yield new insights for obesity biology. Nature. 2015;518(7538):197-206.

28.   Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set

for whole-genome association and population-based linkage analyses. Am J Hum Genet.

2007;81(3):559-75.

29.   Huang dW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists

using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.

30.   Becker KG, Barnes KC, Bright TJ, Wang SA. The genetic association database. Nat Genet.

2004;36(5):431-2.

31.   R Core Team. R: A language and environment for statistical computing. R Foundation for

Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. 2019.

32.   Klok MD, Jakobsdottir S, Drent ML. The role of leptin and ghrelin in the regulation of food

intake and body weight in humans: a review. Obes Rev. 2007;8(1):21-34.

33.   Millard LA, Davies NM, Timpson NJ, Tilling K, Flach PA, Davey Smith G. MR-PheWAS:

hypothesis prioritization among potential causal effects of body mass index on many outcomes, using

Mendelian randomization. Sci Rep. 2015;5:16645.

34.   Gruzdeva O, Borodkina D, Uchasova E, Dyleva Y, Barbarash O. Leptin resistance: underlying

mechanisms and diagnosis. Diabetes Metab Syndr Obes. 2019;12:191-8.

35.   Bodary PF, Westrick RJ, Wickenheiser KJ, Shen Y, Eitzman DT. Effect of leptin on arterial

thrombosis following vascular injury in mice. JAMA. 2002;287(13):1706-9.

36.   Nakata M, Yada T, Soejima N, Maruyama I. Leptin promotes aggregation of human platelets

via the long form of its receptor. Diabetes. 1999;48(2):426-9.

37.   Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, et al. Plasma leptin and

the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS).

Circulation. 2001;104(25):3052-6.

38.   Söderberg S, Ahrén B, Jansson JH, Johnson O, Hallmans G, Asplund K, et al. Leptin is

associated with increased risk of myocardial infarction. J Intern Med. 1999;246(4):409-18.

39.   Furuhashi M, Saitoh S, Shimamoto K, Miura T. Fatty Acid-Binding Protein 4 (FABP4):

Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases.

Clin Med Insights Cardiol. 2014;8(Suppl 3):23-33.

40.   Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, et al. Adipocyte fatty acid-binding protein

is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem.

2006;52(3):405-13.

41.   Gudmundsdottir V, Emilsson V, Aspelund T, Ilkov M, Gudmundsson EF, Zilhão NR, et al.

Deep serum proteomics reveal biomarkers and causal candidates for type 2 diabetes. bioRxiv.

2019:633297.

42.   Nakamura R, Okura T, Fujioka Y, Sumi K, Matsuzawa K, Izawa S, et al. Serum fatty acid-

binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues, A

clinical study. PLoS One. 2017;12(6):e0179737.

43.   Yeung DC, Xu A, Cheung CW, Wat NM, Yau MH, Fong CH, et al. Serum adipocyte fatty acid-

binding protein levels were independently associated with carotid atherosclerosis. Arterioscler Thromb

Vasc Biol. 2007;27(8):1796-802.

44.   Wallace IR, McKinley MC, Bell PM, Hunter SJ. Sex hormone binding globulin and insulin

resistance. Clin Endocrinol (Oxf). 2013;78(3):321-9.

45.   Cooper LA, Page ST, Amory JK, Anawalt BD, Matsumoto AM. The association of obesity with

sex hormone-binding globulin is stronger than the association with ageing--implications for the

interpretation of total testosterone measurements. Clin Endocrinol (Oxf). 2015;83(6):828-33.

46.   Goto A, Chen BH, Song Y, Cauley J, Cummings SR, Farhat GN, et al. Age, body mass,

usage of exogenous estrogen, and lifestyle factors in relation to circulating sex hormone-binding

globulin concentrations in postmenopausal women. Clin Chem. 2014;60(1):174-85.

47.   Baglietto L, English DR, Hopper JL, MacInnis RJ, Morris HA, Tilley WD, et al. Circulating

steroid hormone concentrations in postmenopausal women in relation to body size and composition.

Breast Cancer Res Treat. 2009;115(1):171-9.

48.   Zheng J, Haberland V, Baird D, Walker V, Haycock P, Gutteridge A, et al. Phenome-wide

Mendelian randomization mapping the influence of the plasma proteome on complex diseases.

bioRxiv. 2019:627398.

49.   Jaspers L, Dhana K, Muka T, Meun C, Kiefte-de Jong JC, Hofman A, et al. Sex Steroids, Sex

Hormone-Binding Globulin and Cardiovascular Health in Men and Postmenopausal Women: The

Rotterdam Study. J Clin Endocrinol Metab. 2016;101(7):2844-52.

50.   Nikolaou CK, Hankey CR, Lean MEJ. Accuracy of on-line self-reported weights and heights

by young adults. Eur J Public Health. 2017;27(5):898-903.

51.   Rosengren A, Smyth A, Rangarajan S, Ramasundarahettige C, Bangdiwala SI, AlHabib KF,

et al. Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and

high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. Lancet Glob

Health. 2019;7(6):e748-e60.

52.   Tillmann T, Vaucher J, Okbay A, Pikhart H, Peasey A, Kubinova R, et al. Education and

coronary heart disease: mendelian randomisation study. BMJ. 2017;358:j3542.